Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors

Molecules

Volumn 13, Issue 10, 2008, Pages 2370-2384

  Ito, Takeo ^a   Tanabe, Kazuhito ^a   Yamada, Hisatsugu ^a   Hatta, Hiroshi ^a   Nishimoto, Sei Ichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Hydrated electrons; Hypoxia; Photolysis; Prodrugs; Radiolysis

Indexed keywords

FLUOROURACIL; PRODRUG;

DRUG DELIVERY SYSTEM; HUMAN; IONIZING RADIATION; METHODOLOGY; NEOPLASM; RADIATION EXPOSURE; REVIEW; ULTRAVIOLET RADIATION;

DRUG DELIVERY SYSTEMS; FLUOROURACIL; HUMANS; NEOPLASMS; PRODRUGS; RADIATION, IONIZING; ULTRAVIOLET RAYS;

EID: 55249084962     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules13102370     Document Type: Review

References (65)

1. Rominger, C.J.; Gelber, R.D.; Gunderson, L.L; Conner, N. Radiation-therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery - Radiation-therapy oncology group-study. Am. J. Clin. Oncol. 1985, 8, 118-127.
2. Wolmark, N.; Fisher, B.; Rockette, H.; Redmond, C.; Wickerham, D.L., Fisher, E.R.; Jones, J.; Glass, A.; Lerner, H.; Lawrence, W.; Prager, D.; Wexler, M.; Evans, J.; Cruz, A.; Dimitrov, N.; Jochimsen, P. Postoperative adjuvant chemotherapy or BCG for colon cancer - Results from NSABP protocol-C-01. J. Natl. Cancer Inst. 1988, 80, 30-36.
3. Schwartz, E.L.; Baptiste, N.; Wadler, S.; Makower, D. Thymidine phosphorylase mediates the sensitivity of human colon-carcinoma cells to 5-fluorouracil. J. Biol. Chem. 1995, 270, 19073-19077.
4. Evrard, A.; Cuq, P.; Robert, B.; Vian, L.; Pelegrin, A.; Cano, J.P. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: In vitro and in vivo study. Int. J. Cancer 1999, 80, 465-470.
5. Hartmann, K.U.; Heidelberger, C. Studies on fluorinated pyrimidines. 13. Inhibition of thymidylate synthetase. J. Biol. Chem. 1961, 236, 3006-3013.
6. Peters, G.J.; Vanderwilt, C.L.; Vantriest, B.; Codaccipisanelli, G.; Johnston, P.G.; Vangroeningen, C.J.; Pinedo, H.M. Thymidylate synthase and drug-resistance. Eur. J. Cancer 1995, 31A, 1299-1305.
7. Yeh, K.H.; Shun, C.T.; Chen, C.L.; Lin, J.T.; Lee, W.J.; Lee, P.H.; Chen, Y.C.; Cheng, A.L. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998, 82, 1626-1631.
8. Albert, A. Chemical aspects of selective toxicity. Nature 1958, 182, 421-423.
9. Stella, V.J.; Himmelstein, K.J. Prodrugs and site-specific drug delivery. J. Med. Chem. 1980, 23, 1275-1282.
10. Kratz, F.; Muller I.A.; Ryppa, C.; Warnecke, A.; Prodrug strategies in anticancer chemotherapy. ChemMedChem 2008, 3, 20-53.
11. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R. Oh, D.; Järvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discov. 2008, 7, 255-270.
12. Rooseboom, M.; Commandeur, J.N.M.; Vermeulen, N.P.E. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
13. Yasumoto, M.; Yamawaki, I.; Marunaka, T.; Hashimoto, S. Studies on anti-tumor agents .2. Syntheses and anti-tumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5- fluorouracil. J. Med. Chem. 1978, 21, 738-741.
14. Meyer, R.B.; Levenson, C.H. Structure of two hydroxylated metabolites of ftorafur. Biochem. Pharmacol. 1980, 29, 665-668.
15. Au, J.L.; Sadee, W. The pharmacology of ftorafur (R, S-1-(tetrahydro-2- furanyl)-5-fluorouracil). Recent Results Cancer Res. 1981, 76, 100-114.
16. Iigo, M.; Hoshi, A.; Nakamura, A.; Kuretani, K. Anti-tumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Cancer Chemother. Pharmacol. 1978, 1, 203-208.
17. Sasaki, H.; Takahashi, T.; Mori, Y. Nakamura, J.; Shibasaki, J. Transdermal delivery of 5-fluorouracil and its alkylcarbamoyl derivatives. Int. J. Pharm. 1990, 60, 1-9.
18. Grem, J.L. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs 2000, 18, 299-313.
19. van Laar, J.A.M.; Rustum, Y.M.; Ackland, S.P.; van Groeningen, C.J.; Peters, G.J. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer 1998, 34, 296-306.
20. Denizli, A.; Kiremitci, M.; Piskin, E. Subcutaneous polymeric matrix system p(hema-bga) for controlled release of an anticancer drug (5-fluorouracil). 2. Release kinetics. Biomaterials 1988, 9, 363-366.
21. Endoh, H.; Kawaguchi, T.; Seki, T.; Hasegawa, T.; Juni, K. Controlled release of 5-fluoro-2′-deoxyuridine by the combination of prodrug and polymer matrix. Chem. Pharm. Bull. 1991, 39, 458-464.
22. Kim, K.S.; Kim, T.K.; Graham, N.B. Controlled release behavior of prodrugs based on the biodegradable poly(L-glutamic acid) microspheres. Polym. J. 1999, 31, 813-816.
23. Michael, N.P.; Chester, K.A.; Melton, R.G.; Robson, L.; Nicholas, W.; Boden, J.A.; Pedley, R.B.; Begent, R.H.; Sherwood, R.F.; Minton, N.P. In vitro and in vivo characterisation of a recombinant carboxypeptidase G(2)::anti-CEA scFv fusion protein. Immunotechnology 1996, 2, 47-57.
24. Coelho, V.; Dernedde, J.; Petrausch, U.; Panjideh, H.; Fuchs, H.; Menzel, C.; Dubel, S.; Keilholz, U.; Thiel, E.; Deckert, P.M. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. Int. J. Oncol. 2007, 31, 951-957.
25. Madec-Lougerstay, R.; Florent, J.C.; Monneret, C. Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy. J. Chem. Soc. Perkin Trans. 1 1999, 1369-1375.
26. Fichera, A.; Michelassi, F.; Arenas, R.B. Selective expression of carcinoembryonic antigen promoter in cancer cell lines- Targeting strategy for gene therapy in colorectal cancer. Dis. Colon Rectum. 1998, 41, 747-754.
27. Aquino, A.; Formica, V.; Prete, S.P.; Correale, P.P.; Massara, M.C.; Turriziani, M.; De Vecchis, L; Bonmassar, E. Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol. Res. 2004, 49, 383-396.
28. Topf, N.; Worgall, S.; Hackett, N.R. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral Vector expressing the E-coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther. 1998, 5, 507-513.
29. Denny, W.A. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotechnol. 2003, 48-70.
30. Hatta, H.; Zhou, L.; Mori, M.; Teshima, S.; Nishimoto, S. N(1)-C(5′)-linked dimer hydrates of 5-substituted uracils produced by anodic oxidation in aqueous solution. J. Org. Chem. 2001, 66, 2232-2239.
31. Nishimoto, S.; Hatta, H.; Ueshima, H.; Kagiya, T. 1-(5′-Fluoro- 6′-hydroxy-5′,6′-dihydrouracil-5′-yl)-5-fluorouracil, a novel N(1)-C(5′)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J. Med. Chem. 1992, 35, 2711-2712.
32. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors- A review. Cancer Res.1986, 49, 6449-6465.
33. 2 tension measurements. Cancer Res. 1991, 51, 3316-3322.
34. Denny, W.A. The design of drugs that target tumour hypoxia. Aust. J. Chem. 2004, 57, 821-828.
35. Bruno, R.D.; Njar, V.C.O. Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development. Bioorg. Med. Chem. 2007, 15, 5047-5060.
36. Denny, W.A. Hypoxia-activated anticancer drugs. Expert Opin. Ther. Pat. 2005, 15, 635-646.
37. Tanabe, K.; Zhang, Z.; Ito, T.; Hatta, H.; Nishimoto, S. Current molecular design of intelligent drugs and imaging probes targeting tumor-specic microenvironments. Org. Biomol. Chem. 2007, 5, 3745-3757.
38. von Sonntag, C. Free-Radical-Induced DNA Damage and Its Repair. A Chemical Perspective. Springer-Verlag: Berlin, Heidelberg, Germany, 2006.
39. Mori, M.; Hatta, H.; Nishimoto, S. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2′- oxocycloalkyl)uracils as a new class of radiation-activated antitumor prodrugs. J. Org. Chem. 2000, 65, 4641-4647.
40. Shibamoto, Y.; Zhou, L.; Hatta, H.; Mori, M.; Nishimoto, S. A novel class of antitumor prodrug, 1-(2 ′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Jpn. J. Cancer Res. 2000, 91, 433-438.
41. Shibamoto, Y.; Zhou, L.; Hatta, H.; Mori, M.; Nishimoto, S. In vivo evaluation of a novel antitumor prodrug, 1-(2 ′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 407-413.
42. Tanabe, K.; Mimasu, Y.; Eto, A.; Tachi, Y.; Sakakibara, S.; Mori, M.; Hatta. H.; Nishimoto, S. One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs. Bioorg. Med. Chem. 2003, 11, 4551-4556.
43. Shibamoto, Y.; Mimasu, Y.; Tachi, Y.; Hatta. H.; Nishimoto, S. Comparison of 5-fluorouracil and 5-fluoro-2′-deoxyuridine as an effector in radiation-activated prodrugs. J. Chemother. 2002, 14, 390-396.
44. Shibamoto, Y.; Tachi, Y.; Tanabe, K.; Hatta, H.; Nishimoto, S. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2′- deoxyuridine activated by hypoxic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 397-402.
45. Tanabe, K.; Makimura, Y.; Tachi, Y. Imagawa-Sato, A.; Nishimoto, S. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: Radiolytic reduction and cytotoxicity characteristics. Bioorg. Med. Chem. Lett. 2005, 15, 2321-2324.
46. Naylor, M. A.; Swann, E.; Everett, S. A.; Jaffar, M.; Nolan, J.; Robertson, N.; Lockyer, S. D.; Patel, K. B.; Dennis, M. F.; Stratford, M. R. L.; Wardman, P.; Adams, G. E.; Moody, C. J.; Stratford, I. J. Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl- 4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. J. Med. Chem. 1998, 41, 2720-2731.
47. Swann, E.; Barraja, P.; Oberlander, A. M.; Gardipee, W. T.; Hudnott, A. R.; Beall, H. D.; Moody, C. J. Indolequinone antitumor agents: correlation between quinine structure and rate of metabolism by recombinant human NAD(P)H: quinine oxidoreductase. Part 2. J. Med. Chem. 2001, 44, 3311-3319.
48. Hernick, M.; Flader, C.; Borch, R. F. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. J. Med. Chem. 2002, 45, 3540-3548.
49. Everett, S. A.; Swann, E.; Naylor, M. A.; Stratford, M. R. L.; Patel, K. B.; Tian, A.; Newman, R. G.; Vojnovic, B.; Moody, C. J.; Wardman, P. Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: A key factor in controlling hypoxia-selective drug release. Biochem. Pharmacol. 2002, 63, 1629-1639.
50. Skibo, E. B.; Xing, C.; Groy, T. Recognition and cleavage at the DNA major groove. Bioorg. Med. Chem. 2001, 9, 2445-2459.
51. Dormán, G.; Prestwich, G.D. Using photolabile ligands in drug discovery and development. Trends Biotech. 2000, 18, 64-77.
52. Reinhard, R.; Schmidt, B.F. Nitrobenzyl-based photosensitive phosphoramide mustards: Synthesis and photochemical properties of potential prodrugs for cancer therapy. J. Org. Chem. 1998, 63, 2434-2441.
53. Watanabe, S.; Sato, M.; Sakamoto, S.; Yamaguchi, K.; Iwamura, M. New dendritic caged compounds: synthesis, mass spectrometric characterization, and photochemical properties of dentrimers with a-carboxy-2-nitrobenzyl caged compounds at their periphery. J. Am. Chem. Soc. 2000, 122, 12588-12589.
54. Mizuta, H.; Watanabe, S.; Sakurai, Y.; Nishiyama, K.; Furuta, T.; Kobayashi, Y.; Iwamura, M. Design, synthesis, photochemical properties and cytotoxic activities of water-soluble caged Lleucyl-L-leucine methyl esters that control apoptosis of immune cells. Bioorg. Med. Chem. 2002, 10, 675-683.
55. McCoy, C.P.; Rooney, C.; Edwards, C.R.; Jones, D.S.; Gorman, S.P. Light-triggered molecule-scale drug dosing devices. J. Am. Chem. Soc. 2007, 129, 9572-9573.
56. McCoy, C.P.; Rooney, C.; Jones, D. S.; Gorman, S.P.; Nieuwenhuyzen, M. Rational design of a dual-mode optical and chemical prodrug. Pharm. Res. 2007, 24, 194-200.
57. Tachi, Y.; Dai, W.-M.; Tanabe, K.; Nishimoto, S. Synthesis and DNA cleavage reaction characteristics of enediyne prodrugs activated via an allylic rearrangement by base or UV irradiation. Bioorg. Med. Chem. 2006, 14, 3199-3209.
58. Skwarczynski, M.; Noguchi, M.; Hirota, S.; Sohma, Y.; Kimura, T.; Hayashi, Y.; Kiso, Y. Development of first photoresponsive prodrug of paclitaxel. Bioorg. Med. Chem. Lett. 2006, 16, 4492-4496.
59. Noguchi, M.; Skwarczynski, M.; Prakash, H.; Hirota, S.; Kimura, T.; Hayashi, Y.; Kiso, Y. Development of novel water-soluble photocleavable protecting group and its application for design of photoresponsive paclitaxel prodrugs. Bioorg. Med. Chem. 2008, 16, 5389-5397.
60. Willner, I.; Willner, B. Biological Applications of Photochemical Switches; Morrison, H., Ed; John Wiley & Sons, Inc: New York, USA, 1993.
61. Wei, Y.; Yan, Y.; Pei, D.; Gong, B. A photoactivated prodrug. Bioorg. Med. Chem. Lett. 1998, 8, 2419-2422.
62. Zhang, Z.; Hatta, H.; Ito, T.; Nishimoto, S. Synthesis and photochemical properties of photoactivated antitumor prodrugs releasing 5-fluorouracil. Org. Biomol. Chem. 2005, 3, 592-596.
63. Lin, W.; Peng, D.; Wang, B.; Long, L.; Guo, C.; Yuan, J. A model for light-triggered porphyrin anticancer prodrugs based on an o-nitrobenzyl photolabile group. Eur. J. Org. Chem. 2008, 793-796.
64. Takiuchi, H.; Ajani, J. A. Uracil-tegafur in gastric carcinoma: a comprehensive review. J. Clin. Oncol. 1998, 16, 2877-2885.
65. Sinkel, C.; Greiner, A.; Agarwal, S. Synthesis, characterization, and properties evaluation of methylcoumarin end-functionalized poly(methyl methacrylate) for photoinduced drug release. Macromolecules 2008, 41, 3460-3467.